UPDATE - Dr. Barry Pressman Appointed Chairman of Advanced Medical Isotope's Medical Advisory Board
KENNEWICK, Wash., Nov. 27, 2012 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation ("AMIC") (OTCBB:ADMD), a company engaged in the production and distribution of medical isotopes, is pleased to announce the formation of its Medical Advisory Board.
Chairman of the newly formed Medical Advisory Board is Barry D. Pressman, MD, FACR. Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Center and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, Ca.
Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.
Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard's Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography(CT).
"I am delighted to be appointed to Chair the newly formed Medical Advisory Board (MAB) for AMIC. I anticipate rapid expansion of our MAB, initially focusing on the potential for the Company's brachytherapy products," said Pressman.
James C. Katzaroff, CEO of AMIC, stated, "It is with great pleasure I welcome Dr. Pressman's guidance in assisting the Company to enter the commercial marketplace with its therapeutic products. As AMIC expands beyond the distribution and the production of stable and diagnostic radioisotopes, to the manufacturing of therapeutic products with AMIC's own product line, Dr. Pressman will be instrumental in providing a nationally-recognized practitioner's perspective and expertise that will enable the company to meet the growing needs of a dynamic nuclear medicine marketplace."
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (AMIC) (OTCBB:ADMD) is a U.S.-based public company engaged in the production and distribution of medical isotopes and in the development and identification of medical isotope technologies that are changing the practice of medicine and revolutionizing the standard of medical care.
The Advanced Medical Isotope Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5139
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, including, but not limited to, statements related to AMIC's beliefs and expectations regarding its licensed patents. These statements involve current expectations and beliefs as to future events and other statements that are not historical facts. Known and unknown risks and uncertainties can affect the accuracy of forward-looking statements and cause actual results to differ materially from those anticipated by these forward-looking statements. Factors that could affect actual future events or results include, but are not limited to, risks relating to product development, regulatory approval, sales and marketing, and competition, risks relating to patents, and such other risks as are defined in AMIC's annual report filed by AMIC with the U.S. Securities and Exchange Commission. These forward-looking statements apply only as of the date of this press release, and AMIC undertakes no duty to publicly announce or report revisions to these statements as new information becomes available that may change AMIC's expectations.
CONTACT: James C. Katzaroff, CEO
6208 W. Okanogan Ave.
Kennewick, Wa. 99336